knowledge -WSS

knowledge

author：focus 2025-09-27 09:53:47 - browse：9

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： STAT Boddities: What happens to the brain when we get scared?

entertainment

WSS

The Readout: Lenmeldy, GLP

Congress might make insulin pumps more accessible to the blind

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Abortion pill Supreme Court ruling could impact entire drug industry

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Alkermes shareholders re

Doctors on social media are being harassed and cyberbullied

The cancer drug shortage isn’t new — and neither are the solutions

Ebola vaccine can save some who are already sick, per new study

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Medicare proposal to cover medical devices draws a mixed reaction

Resistance to opioid

Continuity nursing helped my family in our darkest PICU moments

Doctors on social media are being harassed and cyberbullied

leisure time

Resistance to opioid

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Supreme Court mifepristone arguments center on docs' right to sue

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Congress must protect the remaining independent doctors

Why the world’s most expensive drug might be worth the price

focus

entertainment

focus

hotspot